Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high‐...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Exner, Ruth, Sachet, Monika, Arnold, Tobias, Zinn‐Zinnenburg, Mercedes, Michlmayr, Anna, Dubsky, Peter, Bartsch, Rupert, Steger, Guenther, Gnant, Michael, Bergmann, Michael, Bachleitner‐Hofmann, Thomas, Oehler, Rudolf
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5055166/
https://ncbi.nlm.nih.gov/pubmed/27457217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.827
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia